Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 14Salivary Gland Neoplasms 1Prostate Adenocarcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Cisplatin 18Docetaxel 17Cetuximab 12Carboplatin 12Magnetic Resonance Spectroscopy 10pembrolizumab 9Radiotherapy 9Paclitaxel 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Biopsy 7Specimen Handling 6Radiotherapy, Intensity-Modulated 6Radiotherapy, Conformal 5Radiosurgery 5Fluorodeoxyglucose F18 5Chemotherapy, Adjuvant 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Nivolumab 4Bevacizumab 4sargramostim 3Radiation 3Platinum 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Salivary Gland Neoplasms × Glutamate Carboxypeptidase II × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡